Dianomi Therapeutics will work with Ligand on a medication delivery platform based on research from University of Wisconsin-Madison initially targeting pain disorders and osteoarthritis.
Dianomi Therapeutics, a US-based osteoarthritis treatment technology developer based on University of Wisconsin-Madison (UW-Madison) research, obtained $3m in funding on Tuesday under a partnership deal with biotech developer Ligand Pharmaceuticals.
Founded in 2017, Dianomi Therapeutics has licensed a therapeutics delivery technology called Mineral Coated Microparticle (MCM) that sustains biologics and small molecules in the body for longer to help treat pain disorders and osteoarthritis, the latter of which is often treated with surgery at present.
MCM works by exploiting a coating containing human mineralised ingredients such as calcium salts which allow molecules to be released without disruption to their structure, a potential risk prevalent with conventional polymer drug casings.
The hope is that MCM’s durability will facilitate lower dosages for patients, improving safety and treatment outcomes as a result. In addition to treating pain and osteoarthritis, Dianomi believes MCM could be adapted to administer both medications on sale…
